Evaluating CA9hu-1 for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests an experimental drug called CA9hu-1, which targets a protein found on many solid tumors. It is for people with certain advanced cancers that have not responded to standard therapies. The goal is to find a safe dose and see how well the drug controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers that has spread and has not responded to standard treatment: clear cell kidney cancer, triple-negative breast cancer, head and neck cancer, non-small-cell lung cancer, or mesothelioma.
- Your life expectancy is at least 12 weeks, and you are able to do daily activities (performance status 0 or 1).
- Your blood counts and liver and kidney function are within acceptable ranges.
- You have not had radiation therapy to your lungs before.
- You do not have symptomatic brain metastases, spinal cord compression, or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new treatment made from your own immune cells, modified to target a protein called CA9 that is common on clear cell kidney cancer cells. The cells are injected directly into a tumor, and the goal is to see if this can shrink the tumor or slow its growth.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.